TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03960801
Drug: neuromuscular blockade group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus intravenous injection of 1mg/kg of Succinylcholine or Rocuronium after hypnotic administration for a crush anesthetic induction
Study: NCT01949922
Drug: Analgesia
Normalized name: Analgesia Creme Rub
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be offered analgesia as needed during and after surgery. Specific products will depend on allergy and preferences of doctors involved and patient's requirements.
Study: NCT02364258
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Rosuvastatin 10mg tablet (ages 8-21 years); 1 time dose given per oral at the start of the study day.
Study: NCT01067950
Drug: Intensive Insulin Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00766220
Drug: SIR-spheres Agent Administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: SIR-Spheres, resin microspheres containing pure Beta emitter Yttrium-90, given through femoral catheter over 10 minutes.
Study: NCT00797472
Drug: R-mabHD
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: An intravenous infusion containing R-mabHD 375mg/m2 will be administered over a period of 3 to 8 hours every week for eight weeks in a row.
Study: NCT03158376
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01539564
Drug: Minocycline HCl Microspheres
Normalized name: minocycline HCl microspheres
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01519830
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% NaCl solution
Study: NCT02959879
Drug: Standard adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12 cycles of standard adjuvant chemotherapy are administrated
Study: NCT02959879
Drug: adjuvant chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 cycles of standard adjuvant chemotherapy are administrated
Study: NCT02638922
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol containing compounds administered orally in a non-randomized manner.
Study: NCT00774540
Drug: 1 Ketorolac intraarticular
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ketorolac intraarticular 5 mg
Study: NCT00774540
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline
Study: NCT03558295
Drug: Oral Anticoagulant
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: warfarin, dabigatran, rivaroxaban, edoxaban
Study: NCT03043131
Drug: Plasmalyte A
Normalized name: PLASMALYTE A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma Lyte -A is administered intra operatively to maintain the hemodynamic status of patients
Study: NCT03043131
Drug: Ringer Lactate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ringer's lactate is administered intra operatively to maintain the hemodynamic status of patients
Study: NCT02827097
Drug: denogan
Approvals — FDA: no, EMA: no, PMDA: no
Description: administration of denogan
Study: NCT04146805
Drug: Control: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized in a 6:2 ratio to control (matched placebo). Study drug will be administered orally once a with an option to evaluate twice daily dosing (BID) in Part 2 MAD cohort(s).
Study: NCT01195233
Drug: bioxtra
Normalized name: Bioxtra
Approvals — FDA: no, EMA: no, PMDA: no
Description: spray /mouth rinse
Study: NCT02906059
Drug: AZD1775
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03639389
Drug: Analgesics
Normalized name: ANALGESICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of paracetamol + non-steroidal anti-inflammatory drug + morphine to all patients
Study: NCT00577993
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 25 mg/m\^2 IV Days 2 \& 3 of 1st Sequence.
Study: NCT00171145
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets once daily
Study: NCT00577993
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 750 mg/m\^2 IV Day 2 of 1st Sequence.
Study: NCT01663662
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03421119
Drug: Sulfonylurea/non-sulfonylurea insulin secretagogues
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients who were receiving Sulfonylurea/non-sulfonylurea insulin secretagogues with maximum tolerable dose prior to study will continue to receive it during the study.
Study: NCT03357380
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneously (under the skin) once-daily. Will be increased more or less every 4 weeks. It is expected that from week 16 until week 72 The participants take the maximum planned dose (0.4 mg) of study medicine.
Study: NCT02508805
Drug: Neuromultivit
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01978873
Drug: Androgen deprivation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LHRH agonist + antiandrogens for 30 days OR surgical castration OR complete androgen blockade (CAB) by LHRH agonist + antiandrogen device.
Study: NCT01159873
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: up to 5 subcutaneous (sc) doses (given sequentially in cohort groups) of Placebo (0.03, 0.1, 0.3, 1.0, and 3.0 mg/kg) will be studied. After all 5 sc doses have been studied, an intravenous (iv) placebo dose of 0.3 mg/kg will be studied.
Study: NCT02117830
Drug: Androxal 250 Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02117830
Drug: Placebo Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00414479
Drug: praziquantl, iron, ACT
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02017873
Drug: Peroxide Carbamide 10% - Dental bleaching treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: During 3 hours in 3 weeks of bleaching in both groups in healthy patients and smokers patients
Study: NCT03784495
Drug: Melatonin 1mg
Normalized name: MELATONIN 1MG CAP/TAB
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 mg/day 30 minutes before sleep
Study: NCT04160091
Drug: Normal Saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single intra-articular injection
Study: NCT00031863
Drug: rofecoxib
Normalized name: Rofecoxib
DrugBank: Rofecoxib (DB00533)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01659775
Drug: Zofran inj.+Zofran tab.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients were randomized to Sancuso patch or Zofran groups and received the assigned treatment for 5days.~Active Comparator arm: administered intravenously (24mg or 32mg) on Day 1 of chemotherapy and orally (8mg bid) on Day 2-5.
Study: NCT02217566
Drug: Androgen deprivation therapy (ADT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will remain on a stable regimen of ADT, that is, luteinizing hormone-releasing hormone (LHRH) agonists including leuprolide acetate and goserelin acetate as per Investigator's discretion.
Study: NCT02480634
Drug: Zoledronic acid
Normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Comparison the curative effect of the high does radiotherapy and low does therapy after use the Zoledronic acid
Study: NCT02144051
Drug: AZD5312
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD5312 is a generation 2.5 antisense oligonucleotide (ASO) which is designed with the purpose of specifically suppressing human Androgen Receptor (AR) expression, thereby providing potential therapeutic benefit for the treatment of mCRPC and other AR-dependent cancers.
Study: NCT04393610
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive lidocaine 3 mg/kg total of 40 ml plus fentanyl 1 mcg/kg, mixed with lidocaine given after the first 20 ml of block solution.
Study: NCT02004769
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Capecitabine (Xeloda) 2000mg/m2d, d1-14, every 3 weeks until disease progress or intolerable toxicity.
Study: NCT00812864
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pharmacokinetic of its metabolites.~Capecitabine, 1250 mg/m2 twice a day
Study: NCT00252564
Drug: Leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2 on Days 1 and 15
Study: NCT00252564
Drug: Fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 400 mg/m2, IV bolus followed by: 1200 mg/m2/day via 24-hour continuous infusion, for 2 consecutive days (total 5-FU infusion dose = 2400 mg/m2 over the 48 hour period)
Study: NCT02888964
Drug: Add-on therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone therapy
Study: NCT00756171
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 times 3 625mg tablets daily
Study: NCT00133380
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00467597
Drug: Levodopa (delivered intravenously)
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: IV Levodopa is given from 09:00 to 11:00 am during the testing phase of the study. The IV Levodopa allows the researchers to watch one full on and off levodopa cycle while in the inpatient unit.
Study: NCT00634205
Drug: Valproate plus doxorubicin
Normalized name: valproate
DrugBank: Valproic acid (DB00313)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Valproate 20-30 mg/kg orally (in order to obtain serum concentration between 50-100 mcg/ml) Doxorubicin 60 mg/m² intravenously every 3 weeks
Study: NCT00868998
Drug: Gemcitabine, docetaxel, and capecitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Day 1-14: Capecitabine 600 mg/m2/day (maximum dose 2000 mg/m2/day total divided into BID PO doses) Day 4 and 11: Gemcitabine 600 mg/m2 IV over 60 mins Day 4 and 11: Docetaxel 30 mg/m2 IV over 60 mins preceded by 12 mg dexamethasone IV or PO or 4 mg if diabetic
Study: NCT00003209
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00003209
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00070941
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral placebo escitalopram and oral placebo SAM-e daily in two divided doses.
Study: NCT01710722
Drug: caffeine and ephedrine
Normalized name: acetanilide / aspirin / caffeine / ephedrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 200 mg tablets and ephedrine HCl 25 mg tablets three times a day with placebo leptin A-200 subcutaneously once daily.
Study: NCT01710722
Drug: caffeine, ephedrine, and leptin A
Approvals — FDA: no, EMA: no, PMDA: no
Description: Caffeine 200 mg tablets and ephedrine HCl tablets 25 mg three times a day with leptin A-200 20 mg subcutaneously once daily.
Study: NCT01395017
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching Placebo
Study: NCT03195387
Drug: MMV390048
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each tablet contains 20 mg MMV390048 and the following excipients: tartaric acid powder, copovidone (Plasdone S-630), hypromellose acetate succinate (AquaSolve HPMC-AS MF), croscaramellose sodium (Solutab), microcrystalline cellulose type 102 (Avicel PH-102), magnesium stearate (Ligamed MF-2-V).
Study: NCT01782937
Drug: KHK4827
Approvals — FDA: no, EMA: no, PMDA: no
Description: 140 mg (dosage may be increased to 210 mg in case of insufficient efficacy)
Study: NCT01101932
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo solution will be administered to those volunteers who are randomized to the placebo arm. Placebo solution will be administered orally once daily for 14 days.
Study: NCT00441961
Drug: methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: methotrexate
Study: NCT03366428
Drug: DS-8201a
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: DS-8201a is supplied as a lyophilized powder which is reconstituted for infusion
Study: NCT00494078
Drug: intensive insulin therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: intensive insulin therapy according to an algorithm
Study: NCT00405262
Drug: Ketorolac
Normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter
Study: NCT00405262
Drug: ketorolac + bupivacaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mL•kg-1 (lean body mass) bolus of bupivacaine 0.25% with epinephrine 1:200 000 will be injected through the IC catheter at the end surgery before the patient's trachea is extubated to detect intravascular injection. An infusion of the same solution will be started at 0.1 mL•kg-1•hour-1 (lean body mass) for 24 hours.~For ketorolac, patients will receive 0.5 mg•kg-1 IV at the end of surgery before extubation and then 3 additional doses every 8 hours thereafter
Study: NCT00532012
Drug: RhuDex®
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00785603
Drug: Paroxetin placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsules with lactulose to hide, whether the volunteer are receiving 0, 10, 20, 30 or 50 mg paroxetine
Study: NCT01392807
Drug: NKTR-118
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg Oral tablets, single dose
Study: NCT01728987
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule looking identical to the cholecalciferol capsule
Study: NCT00634556
Drug: levodopa solution 2mg/ml for i.v. use
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2mg/mL in normal saline
Study: NCT00634556
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline
Study: NCT02051608
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants received Placebo SC injection Q4W.
Study: NCT01940159
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose placebo
Study: NCT00162656
Drug: half cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00162656
Drug: without COPADM3
Normalized name: threonine
DrugBank: Threonine (DB00156)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00162656
Drug: mini CYVE, without 3 maintenance courses
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00112437
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Odanacatib 3 mg, 10 mg, 25 mg, or 50 once weekly for 24 months
Study: NCT02011828
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablet
Study: NCT00379353
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two placebo capsules orally, once a day for 14 days.
Study: NCT02004691
Drug: placebo (saline)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: solution administered once every two weeks during the 52 weeks of the primary analysis period for participants randomized to placebo.~Route of administration: intravenous infusion
Study: NCT03060070
Drug: control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20ml of 0.25% bupivacaine will be injected in each side of the TAP block
Study: NCT00893945
Drug: DC/AAT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Autologous dendritic cells that have been co-cultured with autologous apoptotic tumor (AAT) specimens.
Study: NCT00893945
Drug: DC/KLH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intradermal injection of Autologous dendritic cell vaccine (DC/KLH) which have been co-cultured with Keyhole pimpit hemocyanin (KLH) as a positive control.
Study: NCT02086838
Drug: low molecular weight iron dextran
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03201276
Drug: Glucosamine Sulfate
Normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients taking glucosamine sulfate 1500mg every day for at least four days.
Study: NCT00284583
Drug: Injection of Steroid into Foot
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00284583
Drug: Injection of Alcohol into Foot
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03513185
Drug: Deanxit, SSRI or SRNI
Approvals — FDA: no, EMA: no, PMDA: no
Description: After recruiting participants and collecting the baseline data, the SSS-CN, PHQ-15, PHQ-9 and GAD-7 questionnaires will be carried out. An independent diagnosis will be made by primary care physician using the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criterion standard. Deanxit, selective serotonin reuptake inhibitors (SSRI) or serotonin-norepinephrine reuptake inhibitors (SNRI) will be selectively prescribed according to the severity category assessed by physician. Two, 6,10 weeks after patients with correspondent medications, a face-to-face interview, telephone interview or mobile-apps survey will be underwent to follow-up using the SSS-CN, PHQ-15, PHQ-9 and GAD-7 checklists.
Study: NCT01189747
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected into bilateral Crow's Feet Line areas on Day 1
Study: NCT02271035
Drug: Deflux
Normalized name: Deflux
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deflux will be injected through the working channel of the cystoscope using a special needle into the submucosal space of the ureteral orifice (Deflux to one ureteral orifice and Vantris to the other side). The technique that will be used is HIT (Hydrodistention Implantation Technique)+ STING
Study: NCT04330547
Drug: Analgesic administration
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Level 1 : Paracétamol 1g/Acetaminophène 1g, Ibuprofène 600mg, Diclofénac 50mg.~* Level 2: Tramadol 50mg.~* Level 3: Oxycodone 5mg, Morphine sulfate 10mg.~* Increase of a prior level 3 medication :~  1. 1/6 of the total dose of daily level 3 medication (e.g. the patient receives 30mg of oxycodone a day. He will be administered a single dose of 5 mg for the study), defined as a breakthrough dose in the management of chronic pain. To standardize the treatment, the dose of the prior level 3 medication will be converted to oxycodone. Several online tools exist to do the conversion between opioids (e.g. mobile app Orthodose ®).~ 2. If the oral intake or the gastrostomy use is not possible, the breakthrough dose will be administered by subcutaneous route. The dose will also be 1/6 of the daily dose and will be converted to injectable morphine. Conversion to injectable morphine will be performed with any equivalence tool (such as the mobile app Orthodose ®)
Study: NCT04330547
Drug: Placebo administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folavit (folic acid, 0.4 mg)
Study: NCT01665404
Drug: RO4917523
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of RO4917523
Study: NCT01049464
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5%D/W 20 ml intravenous in 10 min then 5%D/W 100 ml intravenous in 6 hours.
Study: NCT04980105
Drug: Methylprednisolone acetate injectable suspension (DEPO-MEDROL®)
Normalized name: methylprednisolone acetate Injection
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single methylprednisolone acetate intraarticular injection (DEPO-MEDROL® pfizer 80 mg) mixed with 3cc of (xylocaine 2% concentration)
Study: NCT01625403
Drug: rhBNP
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous administration of rhBNP 0.01 µg/kg/min
Study: NCT00899951
Drug: fentanyl citrate
Normalized name: Fentanyl Citrate
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00902538
Drug: Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 12.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
Study: NCT00902538
Drug: Olmesartan 40mg-Amlodipine 10mg-Hydrochlorothiazide 25mg
Normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablets. All tablets are given once a day.
Study: NCT00902538
Drug: OLM 40mg-AML 10mg-Hydrochlorothiazide 12.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 1 Hydrochlorothiazide 12.5mg oral tablet + 1 Hydrochlorothiazide 12.5mg oral, placebo tablet. All tablets are given once a day.
Study: NCT02927431
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: No vials of placebo to match IV DNX will be provided. A normal saline solution of matched volume will be prepared by unblinded personnel at the site to act as a placebo to DNX. Clear solution of placebo will be administered as IV infusion.
Study: NCT02881086
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02881086
Drug: Mercaptopurine
Normalized name: Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02881086
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02881086
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00902538
Drug: OLM 40mg-AML 10mg-Hydrochlorothiazide 25mg
Normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coated, oral tablets containing Olmesartan 40mg-Amlodipine 10mg + 2 Hydrochlorothiazide 12.5mg oral tablet. All tablets are given once a day.
Study: NCT02387762
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03465202
Drug: Capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT03531827
Drug: CRLX101
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRLX101 is a nanoparticle-drug conjugate (NDC) comprised of a linear cyclodextrin-polyethylene glycol-base polymer conjugated to multiple 2 (S)-camptothecin (CPT) molecules (Poly-CD-PEG-Camptothecin)
Study: NCT02865824
Drug: Continue thienopyridine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients continue dual antiplatelet therapies before colonoscopy. The patients continue taking thienopyridine before colonoscopy